{"id":2129,"date":"2019-08-09T15:18:43","date_gmt":"2019-08-09T14:18:43","guid":{"rendered":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/?p=2129"},"modified":"2019-08-09T15:18:43","modified_gmt":"2019-08-09T14:18:43","slug":"un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela","status":"publish","type":"post","link":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/","title":{"rendered":"Un nou assaig amb masitinib objectiva un alentiment de l\u2019evoluci\u00f3 de l\u2019ELA"},"content":{"rendered":"<p>La Unitat de Motoneurona de l\u2019Hospital Universitari de Bellvitge ha participat en un assaig de masitinib amb 394 pacients d\u2019ELA, seguits durant 48 setmanes, durant les quals s\u2019ha avaluat la caiguda de l\u2019escala funcional, la capacitat vital i la qualitat de vida.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21678421.2019.1632346\">Vegeu l&#8217;assaig (en angl\u00e8s)<\/a><\/li>\n<\/ul>\n<p>A l\u2019estudi s\u2019ha objectivat un alentiment de la caiguda de l\u2019escala funcional que es fa m\u00e9s palesa si es categoritzen els pacients en normal\/lenta progressi\u00f3 i r\u00e0pida progressi\u00f3. Aquest efecte es veu accentuat per la precocitat en l\u2019inici del tractament, es a dir, quan la malaltia est\u00e0 menys evolucionada.<\/p>\n<p>Masitinib \u00e9s un inhibidor de tirosin Kinasa, i realitza un efecte neuroprotector actuant sobre la inmunomodulaci\u00f3 de la glia, macr\u00f2fags i mast\u00f2cits del sistema nervi\u00f3s central i perif\u00e8rico.<\/p>\n<p>Les dades de l\u2019assaig estan sotmeses a l\u2019an\u00e0lisi de l\u2019EMA i ja han servit per plantejar un nou assaig, en el qual tamb\u00e9 participar\u00e0 la Unitat de Motoneurona de l\u2019Hospital de Bellvitge.<\/p>\n<p>Adjuntem tamb\u00e9 <a href=\"https:\/\/www.hindawi.com\/journals\/sci\/2019\/3675627\/\">un altre article (en angl\u00e8s)<\/a> sobre la revisi\u00f3 de c\u00e8l\u00b7lules mare mesenquimals, que comentarem en una entrada posterior.<\/p>\n<p><img loading=\"lazy\" class=\" wp-image-2130\" src=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2019\/08\/c\u00e9lulas-mesenquimales.jpg\" alt=\"\" width=\"326\" height=\"203\" srcset=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2019\/08\/c\u00e9lulas-mesenquimales.jpg 530w, http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2019\/08\/c\u00e9lulas-mesenquimales-300x187.jpg 300w\" sizes=\"(max-width: 326px) 100vw, 326px\" \/><\/p>\n<div class=\"sharedaddy sd-sharing-enabled\"><div class=\"robots-nocontent sd-block sd-social sd-social-icon sd-sharing\"><h3 class=\"sd-title\">Comparteix aix\u00f2:<\/h3><div class=\"sd-content\"><ul><li class=\"share-facebook\"><a rel=\"nofollow\" data-shared=\"sharing-facebook-2129\" class=\"share-facebook sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=facebook\" target=\"_blank\" title=\"Comparteix al Facebook\"><span><\/span><span class=\"sharing-screen-reader-text\">Comparteix al Facebook (Opens in new window)<\/span><\/a><\/li><li class=\"share-twitter\"><a rel=\"nofollow\" data-shared=\"sharing-twitter-2129\" class=\"share-twitter sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=twitter\" target=\"_blank\" title=\"Feu clic per compartir al Twitter\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir al Twitter (Opens in new window)<\/span><\/a><\/li><li class=\"share-google-plus-1\"><a rel=\"nofollow\" data-shared=\"sharing-google-2129\" class=\"share-google-plus-1 sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=google-plus-1\" target=\"_blank\" title=\"Feu clic per compartir a Google+\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir a Google+ (Opens in new window)<\/span><\/a><\/li><li class=\"share-email\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-email sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=email\" target=\"_blank\" title=\"Feu clic per enviar un correu electr\u00f2nic a un amic\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per enviar un correu electr\u00f2nic a un amic (Opens in new window)<\/span><\/a><\/li><li class=\"share-print\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-print sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/\" target=\"_blank\" title=\"Feu clic per imprimir\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per imprimir (Opens in new window)<\/span><\/a><\/li><li class=\"share-end\"><\/li><\/ul><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>La Unitat de Motoneurona de l\u2019Hospital Universitari de Bellvitge ha participat en un assaig de masitinib amb 394 pacients d\u2019ELA, seguits durant 48 setmanes, durant les quals s\u2019ha avaluat la caiguda de l\u2019escala funcional, la capacitat vital i la qualitat &hellip; <a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/\">Continua llegint <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n<div class=\"sharedaddy sd-sharing-enabled\"><div class=\"robots-nocontent sd-block sd-social sd-social-icon sd-sharing\"><h3 class=\"sd-title\">Comparteix aix\u00f2:<\/h3><div class=\"sd-content\"><ul><li class=\"share-facebook\"><a rel=\"nofollow\" data-shared=\"sharing-facebook-2129\" class=\"share-facebook sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=facebook\" target=\"_blank\" title=\"Comparteix al Facebook\"><span><\/span><span class=\"sharing-screen-reader-text\">Comparteix al Facebook (Opens in new window)<\/span><\/a><\/li><li class=\"share-twitter\"><a rel=\"nofollow\" data-shared=\"sharing-twitter-2129\" class=\"share-twitter sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=twitter\" target=\"_blank\" title=\"Feu clic per compartir al Twitter\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir al Twitter (Opens in new window)<\/span><\/a><\/li><li class=\"share-google-plus-1\"><a rel=\"nofollow\" data-shared=\"sharing-google-2129\" class=\"share-google-plus-1 sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=google-plus-1\" target=\"_blank\" title=\"Feu clic per compartir a Google+\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir a Google+ (Opens in new window)<\/span><\/a><\/li><li class=\"share-email\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-email sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/?share=email\" target=\"_blank\" title=\"Feu clic per enviar un correu electr\u00f2nic a un amic\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per enviar un correu electr\u00f2nic a un amic (Opens in new window)<\/span><\/a><\/li><li class=\"share-print\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-print sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/un-nou-assaig-amb-masitinib-objectiva-un-alentiment-de-levolucio-de-lela\/\" target=\"_blank\" title=\"Feu clic per imprimir\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per imprimir (Opens in new window)<\/span><\/a><\/li><li class=\"share-end\"><\/li><\/ul><\/div><\/div><\/div>","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[102,83],"tags":[204,664],"_links":{"self":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts\/2129"}],"collection":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/comments?post=2129"}],"version-history":[{"count":1,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts\/2129\/revisions"}],"predecessor-version":[{"id":2131,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts\/2129\/revisions\/2131"}],"wp:attachment":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/media?parent=2129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/categories?post=2129"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/tags?post=2129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}